Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase

There is a limited understanding of the clinical and molecular factors associated with outcomes of hematopoietic cell transplantation (HCT) in patients with BCR-ABL–negative myeloproliferative neoplasms in blast phase (MPN-BP). Using the Center for International Blood and Marrow Transplant Research...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Gupta, Vikas, Kennedy, James A., Capo-Chichi, Jose-Mario, Kim, Soyoung, Hu, Zhen-Huan, Alyea, Edwin P., Popat, Uday R., Sobecks, Ronald M., Scott, Bart L., Gerds, Aaron T., Salit, Rachel B., Deeg, H. Joachim, Nakamura, Ryotara, Saber, Wael
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656913/
https://ncbi.nlm.nih.gov/pubmed/33170935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados